01:02 PM EDT, 06/11/2025 (MT Newswires) -- Gilead Sciences' ( GILD ) lenacapavir provides "solid" switching opportunities for current users of HIV pre-exposure prophylaxis or PrEP medication, RBC Capital Markets said in a note Wednesday.

Ahead of lenacapavir's potential launch, RBC said it conducted a market research survey on individuals engaged in high-risk behaviors associated with increased HIV infection risk to measure perceptions about PrEP drugs overall and lenacapavir in particular.

"Those currently on PrEP may be 'low hanging fruit' for lena uptake, with physician engagement and payer amenability facilitating," RBC analysts said.

RBC also said that even with the availability of a newer alternative in lena, perceived low HIV risk and disinterest in being on medication could be obstacles.

RBC raised its price target on Gilead to $95 from $92 while maintaining its sector perform rating on the stock.

Price: 110.82, Change: +0.73, Percent Change: +0.66